Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2021 | Alzheimer's Disease | Editorial

The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community

Authors: Valentina Garibotto, Nathalie L. Albert, Henryk Barthel, Bart van Berckel, Ronald Boellaard, Matthias Brendel, Diego Cecchin, Ozgul Ekmekcioglu, Elsmarieke van de Giessen, Eric Guedj, Adriaan A. Lammerstma, Franck Semah, Tatjana Traub-Weidinger, Donatienne Van Weehaeghe, Silvia Morbelli, for the EANM Neuroimaging Committee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2021

Excerpt

On June 7th, 2021, for the first time since 2003, a novel drug against Alzheimer’s disease (AD), aducanumab (Aduhelm™), has been approved in the USA by the Food and Drug Administration (FDA). …

Kuller LH, Lopez OL. ENGAGE and EMERGE: truth and consequences? Alzheimers Dement 2021;17:692–5. https://doi.org/10.1002/alz.12286.CrossRefPubMedPubMedCentral

Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol 2020;19:951–62. S1474–4422(20)30314–8 [pii] https://doi.org/10.1016/S1474-4422(20)30314-8.

Barthel H, Seibyl J, Sabri O. The role of positron emission tomography imaging in understanding Alzheimer’s disease. Expert Rev Neurother 2015;15:395–406. https://doi.org/10.1586/14737175.2015.1023296.CrossRefPubMed

Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement 2015;11:523–32. https://doi.org/10.1016/j.jalz.2014.05.1753.CrossRefPubMed

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement 2017;13:285–95. https://doi.org/10.1016/j.jalz.2016.09.009.CrossRefPubMed

Nath S, Badhiwala JH, Alhazzani W, Nassiri F, Belley-Cote E, Koziarz A, et al. Atraumatic versus traumatic lumbar puncture needles: a systematic review and meta-analysis protocol. BMJ Open 2017;7:e014478. https://doi.org/10.1136/bmjopen-2016-014478.CrossRefPubMedPubMedCentral

Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al. Added value of (18)F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement 2018;14:293–305. https://doi.org/10.1016/j.jalz.2017.09.009.

Ramusino MC, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, et al. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2020;47:270–80. https://doi.org/10.1007/s00259-019-04466[pii].CrossRefPubMed

Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R. Association of amyloid-beta CSF/PET discordance and tau load 5 years later. Neurology 2020;95:e2648–57. https://doi.org/10.1212/WNL.0000000000010739WNL.0000000000010739[pii].CrossRefPubMedPubMedCentral

10.

Ashton NJ, Leuzy A, Karikari TK, Mattsson-Carlgren N, Dodich A, Boccardi M, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging 2021;48:2140–56. https://doi.org/10.1007/s00259-021-05253-y.CrossRefPubMedPubMedCentral

11.

Garibotto V, Boccardi M, Chiti A, Frisoni GB. Molecular imaging and fluid biomarkers of Alzheimer’s disease neuropathology: an opportunity for integrated diagnostics. Eur J Nucl Med Mol Imaging 2021;48:2067–9. https://doi.org/10.1007/s00259-020-05116-y.CrossRefPubMed

12.

Broich K, Weiergraber M, Hampel H. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Prog Neurobiol 2011;95:498–500.CrossRefPubMed

13.

EMA. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease. 2018.

14.

FDA. Early Alzheimer’s disease: developing drugs for treatment. Guidance for Industry. 2018.

15.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRefPubMedPubMedCentral

16.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.CrossRefPubMed

17.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33. https://doi.org/10.1056/NEJMoa1304839.CrossRefPubMedPubMedCentral

18.

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378:321–30. https://doi.org/10.1056/NEJMoa1705971.CrossRefPubMed

19.

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther 2018;10:96. https://doi.org/10.1186/s13195-018-0424-5pii].CrossRefPubMedPubMedCentral

20.

Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 2016;537:50–6. https://doi.org/10.1038/nature19323nature19323[pii].CrossRefPubMed

21.

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med 2021. https://doi.org/10.1056/NEJMoa2100708

22.

Klein G, Delmar P, Kerchner GA, Hofmann C, Abi-Saab D, Davis A, et al. Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J Prev Alzheimers Dis 2021;8:3–6. https://doi.org/10.14283/jpad.2020.68.CrossRefPubMed

23.

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther 2021;13:80. https://doi.org/10.1186/s13195-021-00813-8[pii].CrossRefPubMedPubMedCentral

24.

van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 2013;54:1570–6. https://doi.org/10.2967/jnumed.112.113654jnumed.112.113654[pii].CrossRefPubMed

25.

Barthel H, Seibyl J, Lammertsma AA, Villemagne VL, Sabri O. Exploiting the full potential of beta-amyloid and tau PET imaging for drug efficacy testing. J Nucl Med 2020;61:1105–6. https://doi.org/10.2967/jnumed.119.228346.CrossRefPubMedPubMedCentral

26.

Ossenkoppele R, Prins ND, van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther 2013;5:36. https://doi.org/10.1186/alzrt195.CrossRefPubMedPubMedCentral

27.

Lopes Alves I, Heeman F, Collij LE, Salvado G, Tolboom N, Vilor-Tejedor N, et al. Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther 2021;13:82. https://doi.org/10.1186/s13195-021-00819-2[pii].CrossRefPubMedPubMedCentral

28.

Chincarini A, Peira E, Morbelli S, Pardini M, Bauckneht M, Arbizu J, et al. Semi-quantification and grading of amyloid PET: a project of the European Alzheimer’s Disease Consortium (EADC). Neuroimage Clin 2019;23:101846. https://doi.org/10.1016/j.nicl.2019.101846.CrossRefPubMedPubMedCentral

29.

Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of (18)F-florbetaben PET using a dual-time-window acquisition protocol. J Nucl Med 2018;59:1104–10. https://doi.org/10.2967/jnumed.117.200964.CrossRefPubMed

30.

Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, et al. Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies. EJNMMI Res 2019;9:32. https://doi.org/10.1186/s13550-019-0499-4.CrossRefPubMedPubMedCentral

Title: The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community
Authors: Valentina Garibotto
Nathalie L. Albert
Henryk Barthel
Bart van Berckel
Ronald Boellaard
Matthias Brendel
Diego Cecchin
Ozgul Ekmekcioglu
Elsmarieke van de Giessen
Eric Guedj
Adriaan A. Lammerstma
Franck Semah
Tatjana Traub-Weidinger
Donatienne Van Weehaeghe
Silvia Morbelli
for the EANM Neuroimaging Committee
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Alzheimer's Disease
Alzheimer's Disease
Biomarkers
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05485-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2021

C. Tinoco Mesquita, M. F. Rezende: Nuclear Cardiology Basic and Advanced Concepts in Clinical Practice

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

Explaining a XX century horse behaviour

Prognostic value of coronary vascular dysfunction assessed by rubidium-82 PET/CT imaging in patients with resistant hypertension without overt coronary artery disease

The importance of lung hyperperfusion patterns in COVID-19-related AVDS

Pulmonary tumor thrombotic microangiopathy: the role of a lung perfusion SPECT-CT study